Homeostasis

Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States

Retrieved on: 
月曜日, 6月 3, 2024

“With Blink NutriTears, consumers now have a first-of-its-kind clinically proven nutritional supplement that helps hydrate their eyes from within and provides long-lasting relief.

Key Points: 
  • “With Blink NutriTears, consumers now have a first-of-its-kind clinically proven nutritional supplement that helps hydrate their eyes from within and provides long-lasting relief.
  • It will be an outstanding complement to our growing dry eye portfolio.”*
    Approximately 150 million adults experience symptoms of dry eyes in the United States.
  • It was also shown to clinically help tears stay on the eyes for 33% longer.1*
    "Blink NutriTears demonstrated consistent positive results across two distinct studies.
  • "With its unique formulation, I anticipate Blink NutriTears will become an important addition to dry eye management strategies."

Generation Lab Introduces First Platform that Measures Aging & Treatment Efficacy to Help Extend the Human Healthspan

Retrieved on: 
金曜日, 5月 31, 2024

SAN FRANCISCO, May 31, 2024 (GLOBE NEWSWIRE) -- Generation Lab , the first longevity platform to measurably extend the human lifespan, today announced the general availability of its groundbreaking offering: the first platform that measures aging speed, biomarkers for disease, and top aging factors.

Key Points: 
  • SAN FRANCISCO, May 31, 2024 (GLOBE NEWSWIRE) -- Generation Lab , the first longevity platform to measurably extend the human lifespan, today announced the general availability of its groundbreaking offering: the first platform that measures aging speed, biomarkers for disease, and top aging factors.
  • It offers personalized action plans aimed at cell regeneration across key organs and systems to slow or even reverse aging.
  • One of the first longevity clinics to partner with Generation Lab was New York City’s Extension Health (formerly known as Hudson Health).
  • The Generation Lab platform is available for purchase online or via one of the dozens of longevity clinics across the U.S. in our affiliate program.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
木曜日, 4月 25, 2024

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

Cheap, Independently Produced ‘Junk Gun’ Ransomware Infiltrates the Dark Web, Sophos Finds

Retrieved on: 
水曜日, 4月 17, 2024

Since June 2023, Sophos X-Ops has discovered 19 ‘junk gun’ ransomware variants—cheap, independently produced and crudely constructed ransomware variants—on the dark web.

Key Points: 
  • Since June 2023, Sophos X-Ops has discovered 19 ‘junk gun’ ransomware variants—cheap, independently produced and crudely constructed ransomware variants—on the dark web.
  • The developers of these junk gun variants are attempting to disrupt the traditional affiliate-based ransomware-as-a-service (RaaS) model that has dominated the ransomware racket for nearly a decade .
  • Junk gun ransomware discussions are taking place primarily on English-speaking dark web forums aimed at lower-tier criminals, rather than well-established Russian-speaking forums frequented by prominent attacker groups.
  • To learn more about junk gun ransomware and the latest change in the ransomware ecosystem, read “’Junk Gun’ Ransomware: Peashooters Can Still Pack a Punch” on Sophos.com .

Evolved By Nature Launches Two Biotech Beauty Ingredients at NYSCC

Retrieved on: 
月曜日, 4月 15, 2024

The ingredients, Activated Silk™ 33B and Activated Silk™ 27P, will be showcased by Barentz, the biotech company's North American distribution partner.

Key Points: 
  • The ingredients, Activated Silk™ 33B and Activated Silk™ 27P, will be showcased by Barentz, the biotech company's North American distribution partner.
  • The ingredients are the first two peptides to be launched in Evolved By Nature's ever-expanding Activated Silk™ platform, which is designed to promote three core tenants of skin health – homeostasis, regeneration, and renewal.
  • Activated Silk™ 27P is an innovative bioactive supporting natural collagen production, unlocking unique and powerful efficacies for anti-aging formulas.
  • It's a very exciting time, and NYSCC is the perfect venue for our partner, Barentz, to bring these ingredients to brands looking toward the future", says Germano Coelho, Evolved By Nature's Vice President, Commercial.

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
金曜日, 3月 29, 2024

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

World's first field-installed, clinically approved parallel transmit 7T MRI scanner resides at Auburn University

Retrieved on: 
火曜日, 3月 26, 2024

Additionally, with dedicated radiofrequency sodium imaging coils and parallel transmit technology, the scanner offers expanded imaging capabilities.

Key Points: 
  • Additionally, with dedicated radiofrequency sodium imaging coils and parallel transmit technology, the scanner offers expanded imaging capabilities.
  • These areas represent an intersection between the needs of the MRI research community, particularly in 7T imaging, and existing expertise and strengths of Auburn University.
  • A stark difference between the old and new 7T scanners involve parallel transmit technology and sodium imaging capability.
  • "If it wasn't for them, we wouldn't have the 7T, and we are indebted to them for their dedication and commitment to Auburn.

Gut bacteria and the immune system: How aging changes the microbiome and can lead to ‘inflammaging’

Retrieved on: 
水曜日, 4月 3, 2024

Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.

Key Points: 
  • Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.
  • However, as the composition of our gut microbiome changes with age, a low level of inflammation can become constant throughout the body.
  • Let’s take a closer look at the gut microbiome and how it changes with age.

Gut microbiome imbalances in older adults

  • In fact, compared to other parts of the body, the gut microbiome has the largest number of bacteria.
  • In a healthy gut microbiome, there are four dominant families (or phyla) of microorganisms, including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
  • Firmicutes and Bacteroidetes make up around 80 to 90 per cent of the gut microbiota in the digestive tract.
  • Over time, the shortage of beneficial bacteria such as Firmicutes in older adults starts to compromise the integrity of their intestinal barrier, causing it to become leaky.

How inflammaging works

  • Inflammaging creates an environment that is prone to inflammation, which is caused and maintained by several factors.
  • These can include microorganism imbalances in the intestines (microbial dysbiosis), psychological stress, physical inactivity, poor nutrition and chronic infections.

Maintaining a healthy balance of gut microbiota

  • More specifically, probiotics help improve the function of the intestinal barrier and regulate immune responses by modifying the composition of the gut microbiome.
  • It is clear that the immune system has an intricate relationship with the gut microbiome.
  • A healthy and well-balanced gut microbiome will strengthen the intestinal barrier, which helps to reduce inflammation throughout the body and support the immune system.
  • To achieve this, it is important to maintain a healthy and well-balanced lifestyle as we grow older.


Narveen Jandu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Ocugen to Present at Investing in Cures Summit

Retrieved on: 
水曜日, 3月 6, 2024

MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.

Key Points: 
  • MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.
  • “I look forward to joining my peers in discussing therapeutic approaches to treat inherited retinal diseases that can help slow or reverse degeneration regardless of the underlying genetic cause,” said Dr. Musunuri.
  • “Ocugen’s modifier gene therapy platform can potentially address multiple genetic defects with a single product utilizing a gene agnostic approach that restores homeostasis in the retina.”
    The Investing in Cures Summit includes presentations by the world’s leading industry, clinical and retinal science innovators and is hosted by the Foundation Fighting Blindness and the RD Fund.
  • Details for the panel are as follows:

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Retrieved on: 
月曜日, 3月 4, 2024

LA JOLLA, CA, March 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

Key Points: 
  • The MHRA is the UK regulatory authority, a government agency, for medicines and medical devices.
  • The MHRA is responsible for the regulation of medicines and medical devices and equipment used in healthcare and the investigation of harmful incidents.
  • “We are pleased to receive authorization from the MHRA and take a step in the global expansion of our clinical development for GRI-0621.
  • We are focused on driving this program forward and generating important data readouts this year,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.